Ingo Schmidt‐Wolf

6.8k total citations · 1 hit paper
73 papers, 3.6k citations indexed

About

Ingo Schmidt‐Wolf is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Ingo Schmidt‐Wolf has authored 73 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 20 papers in Hematology and 18 papers in Molecular Biology. Recurrent topics in Ingo Schmidt‐Wolf's work include Multiple Myeloma Research and Treatments (16 papers), Immune Cell Function and Interaction (16 papers) and Cancer Treatment and Pharmacology (9 papers). Ingo Schmidt‐Wolf is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Immune Cell Function and Interaction (16 papers) and Cancer Treatment and Pharmacology (9 papers). Ingo Schmidt‐Wolf collaborates with scholars based in Germany, United States and China. Ingo Schmidt‐Wolf's co-authors include Axel Glasmacher, J. Fahlke, P. Neuhaus, Wolf O. Bechstein, Harald Schmalenberg, Karsten Ridwelski, Hanno Riess, Christof Burkart, Stefan Post and Jan M. Langrehr and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ingo Schmidt‐Wolf

70 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

2007 1.8k citations Ingo Schmidt‐Wolf et al. profile →

Peers

Countries citing papers authored by Ingo Schmidt‐Wolf

Since Specialization

Citations

This map shows the geographic impact of Ingo Schmidt‐Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo Schmidt‐Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo Schmidt‐Wolf more than expected).

Fields of papers citing papers by Ingo Schmidt‐Wolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingo Schmidt‐Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo Schmidt‐Wolf. The network helps show where Ingo Schmidt‐Wolf may publish in the future.

Co-authorship network of co-authors of Ingo Schmidt‐Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Ingo Schmidt‐Wolf. A scholar is included among the top collaborators of Ingo Schmidt‐Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingo Schmidt‐Wolf. Ingo Schmidt‐Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN) 2025 ·European Journal of Nuclear Medicine and Molecular Imaging ·Thomas Büttner, Milka Marinova, Florian Gaertner, (unknown), Louise Fritsche, Chandra Immanuel, (unknown), Stefan Kürpig, (unknown), Ingo Schmidt‐Wolf, Markus Essler, Manuel Ritter, Philipp Krausewitz	0
2	Targeting Cancer With Bifunctional Peptides: Mechanism of Cell Entry and Inciting Cell Death 2025 ·Cancer Science ·(unknown), (unknown), Ingo Schmidt‐Wolf	0
3	191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study 2024 ·Annals of Oncology ·(unknown), Moritz Berger, Farsaneh Sadeghlar, (unknown), (unknown), Christoph Roderburg, (unknown), Friedrich Sinner, Anna Virginia Adriana Pirozzi, (unknown), Ursula Ehmer, Najib Ben Khaled, Thomas J. Ettrich, Matthias Pinter, Ingo Schmidt‐Wolf, Matthias Schmid, Christian P. Strassburg, (unknown)	0
4	The impact of patient engagement on patient safety in care transitions after cancer treatment: Protocol for a systematic review and meta-analysis 2024 ·PLoS ONE ·(unknown), Ingo Schmidt‐Wolf, Matthias Weigl	1
5	Inferring the diagnostic potential of 18F-FDG-PET/CT in post-renal transplantation from a unique case harboring multiple rare complications 2024 ·Frontiers in Medicine ·(unknown), (unknown), (unknown), (unknown), Amit Sharma, Yulu Wang, (unknown), Ingo Schmidt‐Wolf, Ping Lu, (unknown), (unknown)	1
6	Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS Malignancies 2024 ·Cancer Medicine ·(unknown), (unknown), Amit Sharma, (unknown), Ingo Schmidt‐Wolf	2
7	Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt’s lymphoma 2023 ·International Journal of Molecular Sciences ·(unknown), Yulu Wang, Amit Sharma, (unknown), Hongde Liu, Markus Essler, Ulrich Jaehde, Ingo Schmidt‐Wolf	5
8	Assessing the Effects of a Perioperative Nutritional Support and Counseling in Gastrointestinal Cancer Patients: A Retrospective Comparative Study with Historical Controls 2023 ·Biomedicines ·(unknown), (unknown), Birgit Alteheld, Philipp Lingohr, Hanno Matthaei, Tim O. Vilz, Maria A. González-Carmona, (unknown), (unknown), Amit Sharma, Christian P. Strassburg, Jörg C. Kalff, Ingo Schmidt‐Wolf	3
9	Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors 2023 ·International Journal of Molecular Sciences ·(unknown), Amit Sharma, Yutao Li, Ingo Schmidt‐Wolf	8
10	Role of 18F-FDG PET/CT in patients affected by pulmonary primary lymphoma 2022 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Qingyun Zeng, Yujuan Huang, Yulu Wang, Amit Sharma, Ingo Schmidt‐Wolf, (unknown)	7
11	Lenalidomide in multiple myeloma 2015 ·Expert Review of Anticancer Therapy ·Young Kim, Ingo Schmidt‐Wolf	15
12	AML versus ICU: outcome of septic AML patients in an intensive care setting 2015 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Young Ho Kim, (unknown), Peter Brossart, Ingo Schmidt‐Wolf, Peter Walger	11
13	Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care 2010 ·Supportive Care in Cancer ·(unknown), (unknown), Michael Braun, Ulrich Mey, (unknown), Yon Ko, Ingo Schmidt‐Wolf, Walther Kuhn, Ulrich Jaehde	108
14	Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield 2007 ·Leukemia ·Iris Breitkreutz, H M Lokhorst, Marc‐Steffen Raab, Bronno van der Holt, Friedrich W. Cremer, Doris Herrmann, Axel Glasmacher, Ingo Schmidt‐Wolf, Igor Wolfgang Blau, Hans Martin, Hans Salwender, (unknown), Pieter Sonneveld, Hartmut Goldschmidt	40
15	Acquired immunodeficiency syndrome‐related lymphoma 2006 ·Cancer ·(unknown), Paris S. Mitrou, Keikawus Arastéh, Dirk Schuermann, Marcus Hentrich, Ulrich Duehrsen, H. Sudeck, Ingo Schmidt‐Wolf, Ioannis Anagnostopoulos, D. Huhn	65
16	Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance 2006 ·Cancer Genetics and Cytogenetics ·Ingo Schmidt‐Wolf, Axel Glasmacher, Corinna Hahn‐Ast, (unknown), Theresia M. Schnurr, F. W. Cremer, Thomas Moehler, Hartmut Goldschmidt, (unknown), Regine Schubert, Gesa Schwanitz	19
17	SAP and SLAM expression in anti-CD3 activated lymphocytes correlates with cytotoxic activity 2005 ·Immunology and Cell Biology ·Stefan Mehrle, Susanne Frank, Jan Schmidt, Ingo Schmidt‐Wolf, Angela Märten	12
18	Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine 2003 ·British Journal of Cancer ·Carsten Ziske, (unknown), Marcus Gorschlüter, Axel Glasmacher, Ulrich Mey, John Strehl, Tilman Sauerbruch, Ingo Schmidt‐Wolf	136
19	Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules 1999 ·Mycoses ·Axel Glasmacher, Christian Hahn, Ernst Molitor, G. Marklein, Tilman Sauerbruch, Ingo Schmidt‐Wolf	72
20	In vitro and in vivo activity of murine lymphokine‐activated killer cells after cryopreservation 1992 ·Transfusion ·Ingo Schmidt‐Wolf, Miki Aihara, Robert S. Negrin, KG Blume, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact